Characterizing uncertainty and variability in physiologically based pharmacokinetic models: State of the science and needs for research and implementation

Toxicological Sciences

Volumn 99, Issue 2, 2007, Pages 395-402

  Barton, Hugh A ^a   Chiu, Weihsueh A ^a   Woodrow Setzer, R ^a   Andersen, Melvin E ^b   Bailer, A John ^c   Bois, Frédéric Y ^d   Dewoskin, Robert S ^e   Hays, Sean ^f   Johanson, Gunnar ^g   Jones, Nancy ^h   Loizou, George ⁱ   Macphail, Robert C ^a   Portier, Christopher J ^j   Spendiff, Martin ⁱ   Tan, Yu Mei ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^c MIAMI UNIVERSITY   (United States)

^d INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

^e U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^f LLP   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h EC/R Inc   (United States)

ⁱ HEALTH AND SAFETY LABORATORY   (United Kingdom)

^j NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

more..

Author keywords

Bayesian models; Nonlinear modeling; Physiologically based pharmacokinetic modeling; Population variability; Risk assessment; Uncertainty

Indexed keywords

ARTICLE; BAYES THEOREM; BIOLOGICAL MODEL; CALIBRATION; CLINICAL RESEARCH; COMPUTER PROGRAM; DATA BASE; DOSIMETRY; HAZARD ASSESSMENT; HUMAN; INFORMATION PROCESSING; INTERDISCIPLINARY RESEARCH; MEDICAL DOCUMENTATION; NONHUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PREDICTION; REPRODUCIBILITY; RESEARCH PRIORITY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STANDARDIZATION; STATISTICAL MODEL; UNCERTAINTY; ANIMAL; PHARMACOKINETICS;

ANIMALIA;

ANIMALS; CALIBRATION; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 38449107736     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfm100     Document Type: Article

References (40)

1. Andersen, M. E., Clewell, H. J., 3rd, and Frederick, C. B. (1995). Applying simulation modeling to problems in toxicology and risk assessment - A short perspective. Toxicol. Appl. Pharmacol. 133 181-187.
2. Andersen,M. E., Clewell, H. J., 3rd, Gargas, M. L., Smith, F. A., and Reitz, R. H. (1987). Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87, 185-205.
3. Andersen, M. E., Sarangapani, R., Reitz, R. H., Gallavan, R. H., Dobrev, I. D., and Plotzke, K. P. (2001). Physiological modeling reveals novel pharmacokinetic behavior for inhaled octamethylcyclotetrasiloxane in rats. Toxicol. Sci. 60, 214-231.
4. Bischoff, K. B., Dedrick, R. L., Zaharko, D. S., and Longstreth, J. A. (1971). Methotrexate pharmacokinetics. J. Pharm. Sci. 60, 1128-1133.
5. Bois, F. Y., Smith, T., Gelman, A., Chang, H.-Y., and Smith, A. (1999). Optimal design for a study of butadiene toxicokinetics in humans. Toxicol. Sci. 49, 213-224.
6. Bois, F. Y., Smith, M., and Spear, R. C. (1991). Mechanisms of benzene carcinogenesis: Application of a physiological model of benzene pharmacokinetics and metabolism. Toxicol. Lett. 56, 283-298.
7. Brochot, C., Smith, T. J., and Bois, F. Y. Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: Global sensitivity analysis for experimental design issues. Chem. Biol. Interact. 167, 168-183. doi:10.1016/j.cbi.2007.02.010.
8. Buckley, J. J. (1983). Decision making under risk: A comparison of Bayesian and fuzzy set methods. Risk Anal. 3, 157-168.
9. Clark, L. H., Setzer, R.W., and Barton, H. A. (2004). Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. Risk Anal. 24, 1697-1717.
10. Clewell, H. J., 3rd, and Andersen, M. E. (1987). Dose, species, and route extrapolation using physiologically based pharmacokinetic models. In Drinking Water and Health (J. R. Gillette and D. J. Jollow, Eds.), Vol. 8. Pharmacokinetics in Risk Assessment, pp. 159-184. National Academy Press, Washington, DC.
11. Clewell, H. J., Gentry, P. R., Covington, T. R., Sarangapani, R., and Teeguarden, J. G. (2004). Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79, 381-393.
12. Clewell, H. J., 3rd, and Jarnot, B. M. (1994). Incorporation of pharmacokinetics in noncancer risk assessment: Example with chloropentafluorobenzene. Risk Anal. 14, 265-276.
13. Edginton, A. N., Schmitt, W., and Willmann, S. (2006). Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45, 1013-1034.
14. Gargas, M. L., Clewell, H. J., 3rd, and Andersen, M. E. (1990). Gas uptake inhalation techniques and the rates of metabolism of chloromethanes, chloroethanes, and chloroethylenes in the rat. Inhal. Toxicol. 2, 295-319.
15. Gelman, A., Bois, F. Y., and Jiang, J. (1996). Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc. 91, 1400-1412.
16. Georgopoulos, P. G., Roy, A., and Gallo, M. A. (1994). Reconstruction of shortter-multi-route exposure to volatile organiccompounds using physiologically based pharmacokineticmodels. J. Expo. Anal. Environ. Epidemiol. 4, 309-328.
17. Gueorguieva, I., Nestorov, I. A., and Rowland, M. (2004). Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam. J. Pharmacokinet. Pharmacodyn. 31, 185-213.
18. Gueorguieva, I., Nestorov, I. A., and Rowland, M. (2006). Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: Diazepam case study. J. Pharmacokinet. Pharmacodyn. 33, 1-27.
19. Iman, R. L., and Helton, J. C. (1988). An investigation of uncertainty and sensitivity analysis techniques for computer models. Risk Anal. 8, 71-90.
20. Johanson, G., and Naslund, P. H. (1988). Spreadsheet programming - A new approach in physiologically based modeling of solvent toxicokinetics. Toxicol. Lett. 41, 115-127.
21. Jonsson, F., Bois, F., and Johanson, G. (2001). Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol. Sci. 59, 209-218.
22. Jonsson, F., Bois, F. Y., and Johanson, G. (2001). Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. Arch. Toxicol. 75, 189-199.
23. Kalbfleisch, J. D. (1985). Probability and Statistical Inference, Vol. 2. Statistical Inference. New York, Springer Verlag.
24. Knobloch, M., Portier, C. J., Levionnois, O. L., Theurillat, R., Thormann, W., Spadavecchia, C., and Mevissen, M. (2006). Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion. Toxicol. Appl. Pharmacol. 216 373-386
25. Kohn, M. C., and Melnick, R. L. (1996) Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates. Toxicology 113, 31-39.
26. Lehman, S. L., and Stark, L. W. (1982). Three algorithms for interpreting models consisting of ordinary differential equations: Sensitivity coefficients, sensitivity functions, global optimization. Math. Biosci. 62, 107-122.
27. Leung, H. W., Paustenbach, D. J., Murray, F. J., and Andersen, M. E. (1990). A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. Toxicol. Appl. Pharmacol. 103, 399-410.
28. Mezzetti, M., Ibrahim, J. G., Bois, F. Y., Ryan, L. M., Ngo, L., and Smith, T. J. (2003). A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism. J. R. Stat. Soc. Ser. C 52, 291-305.
29. Mork, A. K., and Johanson, G. (2006). A human physiological model describing acetone kinetics in blood and breath during various levels of physical exercise. Toxicol. Lett. 164, 6-15.
30. Müller, P. (1999). Simulation based optimal design. In Bayesian Statistics 6. Proceedings of the Sixth Valencia International Meeting (J. M. Bernardo, J. O. Berger, A. P. Dawid and A. F. M. Smith, Eds.). Oxford University Press, Oxford pp. 323-341.
31. Nestorov, I. A., Aarons, L. J., Arundel, P. A., and Rowland, M. (1998). Lumping of whole-body physiologically based pharmacokinetic models. J. Pharmacokinet. Biopharm. 26, 21-46.
32. Parham, F. M., Kohn, M. C., Matthews, H. B., DeRosa, C., and Portier, C. J. (1997) Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. Toxicol. Appl. Pharmacol. 144, 340-347
33. Reitz, R. H., Quast, J. F., Schumann, A. M.,Watanabe, P. G., and Gehring, P. J. (1980). Non-linear pharmacokinetic parameters need to be considered in high dose/low dose extrapolation. Arch. Toxicol. Suppl. 3, 79-94.
34. Rescigno, A., and Beck, J. S. (1987). The use and abuse of models. J. Pharmacokinet. Biopharm. 15, 327-344
35. Saltelli, A., Tarantola, S., and Campolongo, F. (2000). Sensitivity analysis as an ingredient of modeling. Stat. Sci. 15, 377-395.
36. Singpurwalla, N. D., and Booker, J. M. (2004). Membership functions and probability measures of fuzzy sets, with discussion. J. Am. Stat. Assoc. 99, 467, 867-889.
37. U.S. EPA. (2006). Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment (Final Report). U.S. Environmental Protection Agency, Washington, DC, EPA/600/R-05/043F.
38. WHO/IPCS. (2005). Chemical-Specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/Concentration-Response Assessment. World Health Organization Press, Geneva, Switzerland.
39. Willems, B. A., Melnick, R. L., Kohn, M. C., and Portier, C. J. (2001). A physiologically based pharmacokinetic model for inhalation and intravenous administration of naphthalene in rats and mice. Toxicol. Appl. Pharmacol. 176, 81-91.
40. Willmann, S., Höhn, K., Edginton, A., Sevestre, M., Solodenko, J., Weiss, W., Lippert, J., and Schmitt, W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. (in press). doi: 10.1007/ s10928-007-9053-5.